Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 14/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 5/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 5/20 | 1.00 |
| ▸ | ITGB8 | P26012 | 5/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 4/20 | 1.00 |
| ▸ | ITGA8 | P53708 | 4/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679570 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6683607 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL19090834 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6225944 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6225812 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6805932 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL8334397 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6221693 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224245 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6682740 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | claimed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | claimed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1435967-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | claimed |
| US-6689787-B1 | POTENTIATING TUMOR RESPONSE | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | claimed |
| US-20040024044-A1 | Exemestane as chemopreventing agent | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| EP-1377298-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| EP-1317270-A1 | EXEMESTANE FOR THE TREATMENT OF OESTROGEN-DEPENDENT CANCERS | Pharmacia Italia S.p.A. (IT) | 2003-06-11 | — | — | EP | claimed |
| WO-2003032961-A2 | METHODS FOR PREVENTING AND TREATING BONE LOSS WITH STEROID COMPOUNDS | PHARMACIA ITALIA SPA (IT) | 2003-04-24 | — | — | WO | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| WO-2002020020-A1 | EXEMESTANE AS CHEMOPREVENTING AGENT | PHARMACIA ITALIA S.P.A. (IT) | 2002-03-14 | — | — | WO | claimed |
| EP-1140193-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| EP-1377298-B1 | EXEMESTANE FOR TREATING HORMONO-DEPENDENT DISORDERS | PFIZER ITALIA SRL (IT) | 2006-08-30 | — | — | EP | disclosed |
| EP-1594459-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1140177-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038715-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | ITGB3 9/4885ITGAV 4/4885ITGB6 6/4885 |
| US-20040082557-A1 | Methods for treating estrogen-dependent disorders | CYP19A1, BRCA1, ESR2 | ITGB3 918/4885ITGAV 2117/4885ITGB6 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.